According to a recent news report from Mesothelioma Research News, GlaxoSmithKline (GSK) is working on an experimental drug known as GSK3052230 that has been shown to prevent the growth of mesothelioma in mice. These mice have been implanted with human mesothelioma tumors that are capable of growing in the mice.
The way this investigational drug works is that is prevents tumors from forming or growing by sequestering a particular molecule. This molecule is named a fibroblast growth factor (FGF) molecule. Mesothelioma and various other types of tumors use FBF molecules when they are first forming and growing, because the FGF molecule will allow the tumors to grow new blood vessels. These new blood vessels allow the tumor to get much-needed oxygen and nutrients if they are going to grow larger. Sequestering FGF molecules makes them unavailable to the tumors, which, in turn, will cause the tumor to stop growing. Continue reading